RXST vs. STAA, BHC, WRBY, EYE, EDAP, CLPT, STIM, APYX, BLCO, and VERA
Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include STAAR Surgical (STAA), Bausch Health Companies (BHC), Warby Parker (WRBY), National Vision (EYE), Edap Tms (EDAP), ClearPoint Neuro (CLPT), Neuronetics (STIM), Apyx Medical (APYX), Bausch + Lomb (BLCO), and Vera Therapeutics (VERA). These companies are all part of the "medical" sector.
STAAR Surgical (NASDAQ:STAA) and RxSight (NASDAQ:RXST) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership, community ranking and valuation.
96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.0% of STAAR Surgical shares are owned by company insiders. Comparatively, 21.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
STAAR Surgical received 249 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 56.10% of users gave STAAR Surgical an outperform vote.
STAAR Surgical has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
STAAR Surgical has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
In the previous week, STAAR Surgical had 3 more articles in the media than RxSight. MarketBeat recorded 20 mentions for STAAR Surgical and 17 mentions for RxSight. STAAR Surgical's average media sentiment score of 0.77 beat RxSight's score of 0.25 indicating that RxSight is being referred to more favorably in the news media.
STAAR Surgical has a net margin of 4.69% compared to STAAR Surgical's net margin of -44.01%. RxSight's return on equity of 6.83% beat STAAR Surgical's return on equity.
STAAR Surgical currently has a consensus target price of $47.13, suggesting a potential upside of 7.96%. RxSight has a consensus target price of $60.63, suggesting a potential upside of 0.69%. Given RxSight's higher probable upside, research analysts clearly believe STAAR Surgical is more favorable than RxSight.
Summary
STAAR Surgical beats RxSight on 11 of the 18 factors compared between the two stocks.
Get RxSight News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
